NewsBite

TGA approves weight-loss drug to treat heart disease

Michael Smith
Michael SmithHealth editor
EmailLinkedInTwitterFacebook

Subscribe to gift this article

Gift 5 articles to anyone you choose each month when you subscribe.

Subscribe now

Already a subscriber?

Novo Nordisk, the Danish pharmaceutical giant that makes Wegovy, says as many as 3.5 million Australians could be eligible to access its weight-loss drug after the medicines regulator approved its use to treat heart conditions.

The Therapeutic Goods Administration has approved Wegovy’s application to treat cardiovascular disease in obese and overweight patients in Australia.

Loading...
Michael Smith is the health editor for The Australian Financial Review. He is based in Sydney. Connect with Michael on Twitter. Email Michael at michael.smith@afr.com
EmailLinkedInTwitterFacebook

Subscribe to gift this article

Gift 5 articles to anyone you choose each month when you subscribe.

Subscribe now

Already a subscriber?

License article

Read More

Latest In Healthcare & fitness

Fetching latest articles

Most Viewed In Companies

    The Australian Financial Review Magazine

    BOSS Financial Review

    Sophia Rahmani is the new CEO of Magellan Financial Group.

    Life & Leisure

    Rich List

    Adrian Portelli at the 2024 Melbourne Cup.

    Original URL: https://www.afr.com/companies/healthcare-and-fitness/tga-approves-weight-loss-drug-to-treat-heart-disease-20250217-p5lcr8